WO2010101649A3 - Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection - Google Patents

Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection Download PDF

Info

Publication number
WO2010101649A3
WO2010101649A3 PCT/US2010/000672 US2010000672W WO2010101649A3 WO 2010101649 A3 WO2010101649 A3 WO 2010101649A3 US 2010000672 W US2010000672 W US 2010000672W WO 2010101649 A3 WO2010101649 A3 WO 2010101649A3
Authority
WO
WIPO (PCT)
Prior art keywords
sigma
virus infection
hepatitis
against hepatitis
receptor inhibition
Prior art date
Application number
PCT/US2010/000672
Other languages
French (fr)
Other versions
WO2010101649A2 (en
Inventor
Pablo Gastaminza
Francis Chisari
Original Assignee
Pablo Gastaminza
Francis Chisari
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pablo Gastaminza, Francis Chisari filed Critical Pablo Gastaminza
Publication of WO2010101649A2 publication Critical patent/WO2010101649A2/en
Publication of WO2010101649A3 publication Critical patent/WO2010101649A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for treating or ameliorating the symptoms of a Hepatitis C virus infection comprising administering a Sigma 1 receptor binding compound or an interfering RNA is provided. Methods for identifying a compound that inhibits a Hepatitis C virus infection are also provided. The Sigma 1 receptor binding compound or interfering RNA is believed to act by reducing the susceptibility of uninfected human cells to infection by Hepatitis C virus, inhibiting viral spread in a cellular population.
PCT/US2010/000672 2009-03-05 2010-03-05 Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection WO2010101649A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15758709P 2009-03-05 2009-03-05
US61/157,587 2009-03-05

Publications (2)

Publication Number Publication Date
WO2010101649A2 WO2010101649A2 (en) 2010-09-10
WO2010101649A3 true WO2010101649A3 (en) 2011-01-13

Family

ID=42710156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/000672 WO2010101649A2 (en) 2009-03-05 2010-03-05 Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection

Country Status (1)

Country Link
WO (1) WO2010101649A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2011161644A1 (en) * 2010-06-24 2011-12-29 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
FR2970869B1 (en) * 2011-01-31 2013-09-06 Centre Nat Rech Scient USE OF THE SIGMA-1 RECEPTOR FOR REGULATING THE EXPRESSION OF IONIC CHANNELS AT THE POST-TRANSCRIPTIONAL LEVEL
EP2723337A1 (en) 2011-06-23 2014-04-30 Panmed Ltd. Treatment of hepatitis c virus
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN103826627B (en) 2011-10-21 2016-02-24 艾伯维公司 Comprise the purposes of compositions in the medicine of preparation treatment HCV of at least two kinds of direct antiviral agent and ribavirin
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
WO2013178782A1 (en) * 2012-05-30 2013-12-05 Universidad De Zaragoza Allosteric inhibitors of ns3 protease from hepatitis c virus
CN102976955A (en) * 2012-12-14 2013-03-20 南京工业大学 Method for refining cyclobenzaprine hydrochloride
US20170001988A1 (en) * 2013-11-27 2017-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Piperidine and piperazine derivatives and their use in treating viral infections and cancer
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS
CN108721264B (en) * 2017-04-13 2020-07-10 中国科学院武汉病毒研究所 Application of isoxsuprine in preparing medicine for treating or preventing influenza virus infection
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
WO2021252709A1 (en) * 2020-06-10 2021-12-16 Rutgers, The State University Of New Jersey Compounds, compositions, and methods for treating, ameliorating, and/or preventing sigma receptor related diseases and/or disorders
CN113603642A (en) * 2020-11-16 2021-11-05 上海中西三维药业有限公司 Hydroxychloroquine sulfate hydrate, crystal form thereof, preparation method and application thereof
CN114177176B (en) * 2021-12-04 2022-07-12 中国农业科学院兰州兽医研究所 Application of compound cyproheptadine hydrochloride in preparation of drug for preventing or treating African swine fever

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030229082A1 (en) * 2002-01-16 2003-12-11 The Regents Of The University Of California Inhibition of RNA function
US20040019060A1 (en) * 2000-03-31 2004-01-29 Spruce Barbara Ann Sigma receptor ligands and their medical uses
WO2008021353A2 (en) * 2006-08-14 2008-02-21 Guangxiang Luo Composition and method for controlling hepatitis c virus infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019060A1 (en) * 2000-03-31 2004-01-29 Spruce Barbara Ann Sigma receptor ligands and their medical uses
US20030229082A1 (en) * 2002-01-16 2003-12-11 The Regents Of The University Of California Inhibition of RNA function
WO2008021353A2 (en) * 2006-08-14 2008-02-21 Guangxiang Luo Composition and method for controlling hepatitis c virus infection

Also Published As

Publication number Publication date
WO2010101649A2 (en) 2010-09-10

Similar Documents

Publication Publication Date Title
WO2010101649A3 (en) Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection
WO2011106106A3 (en) Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
MX2012004032A (en) Compounds for the treatment of hepatitis c.
PH12015501678A1 (en) Inhibitors of influenza viruses replication
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
MX2009009473A (en) Compounds for the treatment of hepatitis c.
WO2012083122A8 (en) Inhibitors of influenza viruses replication
WO2008100867A3 (en) Novel inhibitors hepatitis c virus replication
MX2010008749A (en) Hepatitis c virus inhibitors.
TN2012000264A1 (en) Hepatitis c virus inhibitors
MX2013006846A (en) Inhibitors of influenza viruses replication.
MY152971A (en) Hepatitis c virus inhibitors
EP2853531A3 (en) Antiviral compounds
MX2011008045A (en) Hepatitis c virus inhibitors.
MX2013003634A (en) Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases.
EA201200890A1 (en) Combined HCV therapy
MX2010009563A (en) Chemical compounds having antiviral activity against dengue virus and other flaviviruses.
IL178679A0 (en) Methods and compositions for reducing viral genome amounts in a target cell
MX2010008531A (en) Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors.
EA202191537A1 (en) COMPOSITIONS AND METHODS FOR INHIBITION OF HEPATITIS B VIRUS GENE EXPRESSION
UA118010C2 (en) INFLUENCES OF INFLUENZA VIRUS REPLICATION
WO2009026176A3 (en) Antiinfective flavononol compounds and methods of use thereof
WO2009148961A3 (en) Drugs to prevent hpv infection
MX337936B (en) Hepatitis c virus inhibitors.
SG170751A1 (en) Extractions and methods comprising elder species

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10749060

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 16.11.11)

122 Ep: pct application non-entry in european phase

Ref document number: 10749060

Country of ref document: EP

Kind code of ref document: A2